Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Prasugrel Re-load Strategies
Impact of Prasugrel Re-load on Platelet Aggregation in Patients on Chronic Prasugrel Therapy
Status: Archived
University of Florida Gainesville
mi
from
Gainesville, FL
Prasugrel Re-load Strategies
Impact of Prasugrel Re-load on Platelet Aggregation in Patients on Chronic Prasugrel Therapy
Status: Archived
Updated: 1/1/1970
University of Florida Gainesville
mi
from
Gainesville, FL
Split Thickness Donor Site Pilot Study
A Prospective, Randomized, Controlled Pilot Study of the MIST Therapy System for the Treatment of Split Thickness Donor Sites
Status: Archived
James A. Haley VA Hospital
mi
from
Tampa, FL
Split Thickness Donor Site Pilot Study
A Prospective, Randomized, Controlled Pilot Study of the MIST Therapy System for the Treatment of Split Thickness Donor Sites
Status: Archived
Updated: 1/1/1970
James A. Haley VA Hospital
mi
from
Tampa, FL
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Jeffersonville, IN
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jeffersonville, IN
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Albuquerque, NM
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albuquerque, NM
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Ponca City, OK
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ponca City, OK
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Evaluation of Left Ventricular Autothreshold, Phase Two
Evaluation of Left Ventricular Autothreshold, Phase Two
Status: Archived
Regional Cardiovascular Medical Center
mi
from
Steubenville, OH
Evaluation of Left Ventricular Autothreshold, Phase Two
Evaluation of Left Ventricular Autothreshold, Phase Two
Status: Archived
Updated: 1/1/1970
Regional Cardiovascular Medical Center
mi
from
Steubenville, OH
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Durham Family Practice
mi
from
Durham, NC
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Updated: 1/1/1970
Durham Family Practice
mi
from
Durham, NC
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Dayspring Family Medicine
mi
from
Eden, NC
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Updated: 1/1/1970
Dayspring Family Medicine
mi
from
Eden, NC
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Cabarrus Family Medicine Residency
mi
from
Kannapolis, NC
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Updated: 1/1/1970
Cabarrus Family Medicine Residency
mi
from
Kannapolis, NC
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Moncure Community Health Center
mi
from
Moncure, NC
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Updated: 1/1/1970
Moncure Community Health Center
mi
from
Moncure, NC
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Caswell Family Medical Clinic
mi
from
Yanceyville, NC
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
A Combined Lifestyle and Medication Intervention to Reduce CVD Risk
Status: Archived
Updated: 1/1/1970
Caswell Family Medical Clinic
mi
from
Yanceyville, NC
The Safety of Vardenafil in Patients Undergoing Cardiac Surgery
The Safety of Vardenafil in Patients Undergoing Cardiac Surgery
Status: Archived
McGuire Veterans Administration Medical Center
mi
from
Richmond, VA
The Safety of Vardenafil in Patients Undergoing Cardiac Surgery
The Safety of Vardenafil in Patients Undergoing Cardiac Surgery
Status: Archived
Updated: 1/1/1970
McGuire Veterans Administration Medical Center
mi
from
Richmond, VA
Safety and Tolerability of RNS60 Given by IV to Healthy Subjects
Phase I, Double-blind, Randomized, Placebo-controlled, Single-center Study to Assess the Safety and Tolerability of RNS60 Administered Intravenously to Healthy Subjects
Status: Archived
Quintiles, Inc.
mi
from
Overland Park, KA
Safety and Tolerability of RNS60 Given by IV to Healthy Subjects
Phase I, Double-blind, Randomized, Placebo-controlled, Single-center Study to Assess the Safety and Tolerability of RNS60 Administered Intravenously to Healthy Subjects
Status: Archived
Updated: 1/1/1970
Quintiles, Inc.
mi
from
Overland Park, KA
The Jackson Heart Study of Cardiovascular Disease Among African Americans
The Jackson Heart Study of Cardiovascular Disease Among African Americans
Status: Enrolling
Updated:  12/31/1969
Tougaloo College
mi
from
Jackson, MS
The Jackson Heart Study of Cardiovascular Disease Among African Americans
The Jackson Heart Study of Cardiovascular Disease Among African Americans
Status: Enrolling
Updated: 12/31/1969
Tougaloo College
mi
from
Jackson, MS
Click here to add this to my saved trials
The Jackson Heart Study of Cardiovascular Disease Among African Americans
The Jackson Heart Study of Cardiovascular Disease Among African Americans
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center Department of Medicine
mi
from
Jackson, MS
The Jackson Heart Study of Cardiovascular Disease Among African Americans
The Jackson Heart Study of Cardiovascular Disease Among African Americans
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center Department of Medicine
mi
from
Jackson, MS
Click here to add this to my saved trials
The Jackson Heart Study of Cardiovascular Disease Among African Americans
The Jackson Heart Study of Cardiovascular Disease Among African Americans
Status: Enrolling
Updated:  12/31/1969
Jackson State University
mi
from
Jackson, MS
The Jackson Heart Study of Cardiovascular Disease Among African Americans
The Jackson Heart Study of Cardiovascular Disease Among African Americans
Status: Enrolling
Updated: 12/31/1969
Jackson State University
mi
from
Jackson, MS
Click here to add this to my saved trials
Technical Development of Cardiovascular Magnetic Resonance Imaging
Technical Development of Cardiovascular Magnetic Resonance Imaging
Status: Enrolling
Updated:  12/31/1969
Suburban Hospital
mi
from
Bethesda, MD
Technical Development of Cardiovascular Magnetic Resonance Imaging
Technical Development of Cardiovascular Magnetic Resonance Imaging
Status: Enrolling
Updated: 12/31/1969
Suburban Hospital
mi
from
Bethesda, MD
Click here to add this to my saved trials
Technical Development of Cardiovascular Magnetic Resonance Imaging
Technical Development of Cardiovascular Magnetic Resonance Imaging
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Technical Development of Cardiovascular Magnetic Resonance Imaging
Technical Development of Cardiovascular Magnetic Resonance Imaging
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pivotal Study of a Percutaneous Mitral Valve Repair System
Pivotal Study: A Study of the Evalve Cardiovascular Valve Repair System - Endovascular Valve Edge-to-Edge REpair STudy (EVERESTIIRCT)
Status: Enrolling
Updated:  12/31/1969
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Pivotal Study of a Percutaneous Mitral Valve Repair System
Pivotal Study: A Study of the Evalve Cardiovascular Valve Repair System - Endovascular Valve Edge-to-Edge REpair STudy (EVERESTIIRCT)
Status: Enrolling
Updated: 12/31/1969
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Click here to add this to my saved trials
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
Status: Enrolling
Updated:  12/31/1969
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
Status: Enrolling
Updated: 12/31/1969
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
Treatment of Orthostatic Intolerance
Treatment of Orthostatic Intolerance
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Autonomic Dysfunction Center
mi
from
Nashville, TN
Treatment of Orthostatic Intolerance
Treatment of Orthostatic Intolerance
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Autonomic Dysfunction Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematopoietic Stem Cell Support in Vasculitis
High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Hematopoietic Stem Cell Support in Vasculitis
High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Ventricular Tachyarrhythmia (VT) Storm, Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm
Gene Expression in ICD Patients With Electrical Storm
Status: Enrolling
Updated:  12/31/1969
UPMC Presbyterian Hospital
mi
from
Pittsburgh, PA
Ventricular Tachyarrhythmia (VT) Storm, Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm
Gene Expression in ICD Patients With Electrical Storm
Status: Enrolling
Updated: 12/31/1969
UPMC Presbyterian Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Ventricular Tachyarrhythmia (VT) Storm, Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm
Gene Expression in ICD Patients With Electrical Storm
Status: Enrolling
Updated:  12/31/1969
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Ventricular Tachyarrhythmia (VT) Storm, Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm
Gene Expression in ICD Patients With Electrical Storm
Status: Enrolling
Updated: 12/31/1969
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)
Reduce Ventricular Pacing Using Ventricular Intrinsic Preference: VIP™ Study
Status: Enrolling
Updated:  12/31/1969
St. Jude Medical
mi
from
Sylmar, CA
Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)
Reduce Ventricular Pacing Using Ventricular Intrinsic Preference: VIP™ Study
Status: Enrolling
Updated: 12/31/1969
St. Jude Medical
mi
from
Sylmar, CA
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Meridian, ID
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Evanston, IL
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Anderson, IN
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Anderson, IN
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Des Moines, IA
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Des Moines, IA
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kansas City, KA
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials